

Princess Cruise Lines, Ltd., P & O Princess Cruises International Limited and P & O Princess Cruises plc
24305 Town Center Drive
Santa Clarita, CA 91355-4999
Vessel: *Pacific Princess*

RCL (UK) Ltd. (d/b/a Royal Caribbean International)
Royal Caribbean House
Addlestone Road
Weybridge, Surrey KT15 2LLE
England
Vessel: *Brilliance of the Seas*

Royal Caribbean Cruises Ltd. (d/b/a Royal Caribbean International)
1050 Caribbean Way
Miami, FL 33132-2096
Vessels: *Jewel of the Seas, Mariner of the Seas Navigator of the Seas and Serenade of the Seas*

Royal Olympic Cruises Ltd
805 3rd Avenue, 18th Floor
New York, NY 10022
Vessels: *Lymphia Explorer and Lymphia Voyager*

Silversea Cruises, Ltd. and Silver Cloud Shipping Company S.A.
110 East Broward Blvd.
Fort Lauderdale, FL 33301
Vessel: *Silver Cloud*

Dated: December 13, 2002.

Bryant L. VanBrakle,
Secretary.

[FR Doc. 02-31879 Filed 12-17-02; 8:45 am]

BILLING CODE 6730-01-P

FEDERAL MARITIME COMMISSION

Ocean Transportation Intermediary License Applicant

Notice is hereby given that the following applicant has filed with the Federal Maritime Commission an application for license as a Non-Vessel Operating Common Carrier and Ocean Freight Forwarder—Ocean Transportation Intermediary pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. app. 1718 and 46 CFR 515).

Persons knowing of any reason why the following applicant should not receive a license are requested to contact the Office of Transportation Intermediaries, Federal Maritime Commission, Washington, DC 20573.

Non-Vessel Operating Common Carrier and Ocean Freight Forwarder Transportation Intermediary Applicant: Speedier Logistics (U.S.A.), Inc., 147-39 175th Street, Room 215, Jamaica, NY 11434. Officer: Richard Ying, President (Qualifying Individual).

Dated: December 13, 2002.

Bryant L. VanBrakle,
Secretary.

[FR Doc. 02-31877 Filed 12-17-02; 8:45 am]

BILLING CODE 6730-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Public Health and Science; Office of the Secretary

Request for Nominations for Members of the Chronic Fatigue Syndrome Advisory Committee

The Office of Public Health and Science (OPHS), Department of Health and Human Services (DHHS), request nominations for representatives to serve on the Chronic Fatigue Syndrome Advisory Committee (CFSAC). Nominations are solicited for biomedical research scientists with demonstrated achievements in biomedical research relating to Chronic Fatigue Syndrome (CFS); individuals with expertise in health care delivery, private health care services or insurers, or voluntary organizations concerned with the problems of individuals with CFS.

DHHS has a strong interest in ensuring that women, minority groups, and physically challenged individuals are adequately represented on the Committee and, therefore, encourages nominations of qualified candidates from these groups. DHHS also encourages geographic diversity in the composition of the Committee.

Information Required: A nomination package must include the following information for each nominee:

1. A letter of nomination stating the name, affiliation, and contact information for the nominee, the basis for the nomination (i.e., what specific attributes recommend him/her for service in this capacity), and the nominee's area of expertise;
 2. A biographical sketch of the nominee and a copy of his or her curriculum vitae; and
 3. The name, return address, and daytime telephone number at which the nominator can be contacted.
- Organizational nominators must identify a principal contact person in addition to contact information. Optimally, a nomination package would also include a statement by the nominee that he/she is willing to accept an appointment to Committee membership.

All nomination information for a nominee must be provided in a complete single package within 45 days of the publication of this notice. Incomplete nominations cannot be considered. The nomination letter must bear an original signature; facsimile transmissions or copies are not acceptable.

DATES: All nominations must be received at the address below no later

than 4 p.m. EDT within 45 days of the publication of this notice.

ADDRESSES: All nomination packages shall be submitted to Debra Nichols, MD, MPH, Executive Secretary, CFSAC, Office of Disease Prevention and Health Promotion, 200 Independence Ave, Room 738G, Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT:

Debra Nichols, MD at the above address or at 202-401-0735, or e-mail at dnichols@osophs.dhhs.gov.

Dated: December 6, 2002.

Debra Nichols,

Executive Secretary, CFSAC, Office of Disease Prevention and Health Promotion, Office of Public Health and Science, DHHS.

[FR Doc. 02-31829 Filed 12-17-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Proposed Research Protocol: Precursors to Diabetes in Japanese American Youth

AGENCY: Office of the Secretary, Office of Public Health and Science, Office for Human Research Protections.

ACTION: Notice.

SUMMARY: On August 7, 2002, the Office of Human Research Protections (OHRP), Office of Public Health and Science, Department of Health and Human Services (HHS), gave notice (67 FR 51283) that it was proposing to recommend approval of HHS support for the research protocol entitled "Precursors to Diabetes in Japanese American Youth," subject to a stipulation that certain modifications be made to the protocol and consent forms. OHRP is reopening the period for public comment and is making available additional information regarding the protocol.

DATES: To be considered, written or electronic comments must be received on or before January 17, 2003.

ADDRESSES: Submit written comments to: Kelley Booher, Division of Policy, Planning, and Special Projects, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, The Tower Building, Rockville, MD 20852, telephone number (301) 402-5942 (not a toll free number). Comments also may be sent via facsimile at (301) 402-2071 (not a toll free number) or by e-mail to: kbooher@osophs.dhhs.gov.

SUPPLEMENTARY INFORMATION: On August 7, 2002, the Office for Human Research Protections published a notice in the **Federal Register**, 67 FR 51283 (<http://frwebgate.access.gpo.gov/cgi-bin/>

[getdoc.cgi?dbname=2002_register&docid=02-19871-filed.pdf](http://www.fda.gov/oc/ohrp/getdoc.cgi?dbname=2002_register&docid=02-19871-filed.pdf)), soliciting comments on its proposal to recommend approval on HHS support for the research protocol entitled "Precursors to Diabetes in Japanese American Youth" (1 R01 DK59234-01). The comment period closed on August 21, 2002. OHRP hereby gives notice that the comment period is being reopened for 30 days, and additional information regarding the protocol is being made available.

OHRP received a number of comments in response to the August 7, 2002, notice. Several who commented stated that (1) the 14-day comment period was too short, and (2) the information about the research protocol that OHRP provided to the public was insufficient to allow for meaningful comment about whether the research was appropriate for HHS to support. In response to these comments, OHRP is reopening the public comment period for 30 days. OHRP also is making available additional information regarding the research protocol, namely: the protocol application reviewed by the Children's Hospital and Regional Medical Center (Seattle) IRB; the assent form; the consent form; and selected parts of the grant application, including the abstract, specific aims, background and significance, discussion of the involvement of human subjects, and literature cited. These materials are available for review on the OHRP Web page at (<http://ohrp.osophs.dhhs.gov/pdjay/pdjayindex.htm>). A paper copy of the information referenced here is available upon request.

FOR FURTHER INFORMATION CONTACT: Requests for additional information about the research proposal may be submitted under the Freedom of Information Act (FOIA). Such requests should be directed to: Ms. Darlene Christian, PHS FOIA Office, Parklawn

Building, Room 17A-46, 5600 Fishers Lane, Rockville, MD 20857; telephone (301) 443-5252; fax (301) 443-0925.

Dated: December 12, 2002.

Eve E. Slater,

Assistant Secretary for Health.

[FR Doc. 02-31848 Filed 12-17-02; 8:45 am]

BILLING CODE 4150-28-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY-07-03]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 498-1210. Send written comments to CDC, Desk Officer, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503. Written comments should be received within 30 days of this notice.

Proposed Project: Requirement for a Special Permit to Import Cynomolgus, African Green, or Rhesus Monkeys into the United States (0920-0263)—*Extension*—National Center for Infectious Diseases (NCID), Centers for Disease Control and Prevention (CDC). To receive a special permit to import cynomolgus, African green and/or rhesus monkeys, a registered importer of nonhuman primates must submit to the Director, CDC, a written plan which specifies the steps that will be taken to prevent exposure of persons and

animals during the entire importation and quarantine process for the arriving nonhuman primates.

Under the special permit arrangement, registered importers must submit a plan to CDC for the importation and quarantine if they wish to import the specific monkeys covered. The plan must address disease prevention procedures to be carried out in every step of the chain of custody of such monkeys, from embarkation in the country of origin to release from quarantine. Information such as species, origin and intended use for monkeys, transit information, isolation and quarantine procedures, and procedures for testing of quarantined animals is necessary for CDC to make public health decisions. This information enables CDC to evaluate compliance with the standards and determine whether the measures being taken to prevent exposure of persons and animals during importation are adequate. Once CDC is assured, through the monitoring of shipments (normally no more than 2), that the provisions of a special permit plan are being followed by a new permit holder and that the use of adequate disease control practices is being demonstrated, the special permit is extended to cover the receipt of additional shipments under the same plan for a period of 180 days, and may be renewed upon request. This eliminates the burden on importers to repeatedly report identical information, requiring only that specific shipment itineraries and information on changes to the plan which require approval be submitted.

Respondents are commercial or not-for-profit importers of nonhuman primates. The burden represents full submission of information and itinerary/change information respectively. The burden hours are estimated to be approximately 20.

Respondents	Number of respondents	Number of responses per respondents	Avg. burden responses (in hrs.)
Businesses	2	5	30/60
	3	5	10/60
Organizations (limited permit)	15	5	10/60